Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing Strategy

Business Wire May 2, 2023

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update

Business Wire May 1, 2023

MindMed to Participate in May Investor Conferences

Business Wire April 26, 2023

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Business Wire April 18, 2023

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

Business Wire April 14, 2023

MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary

Business Wire April 13, 2023

MindMed Reports Full Year 2022 Financial Results and Business Highlights

Business Wire March 9, 2023

MindMed to Participate in March Investor Conferences

Business Wire February 28, 2023

Trippy Trading: Top Psychedelic Stocks For 2023

TheNewsWire January 17, 2023

MindMed Provides Corporate Update and 2023 Outlook

PR Newswire January 9, 2023

MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference

PR Newswire December 1, 2022

MindMed to Participate in the Jefferies London Healthcare Conference

PR Newswire November 11, 2022

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

PR Newswire November 10, 2022

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

PR Newswire November 3, 2022

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

PR Newswire October 5, 2022

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

PR Newswire October 4, 2022

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign

PR Newswire September 28, 2022

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

PR Newswire September 27, 2022

MindMed Announces Proposed Public Offering of Common Shares

PR Newswire September 27, 2022

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

PR Newswire September 20, 2022